Some people skeptical thinking its fake because it’s China. Well, here’s some of the BIGGEST drug breakthroughs from China in the last 3 years:
1. Hemophilia B AAV gene therapy. First hemophilia B gene therapy approved in China; single IV AAV infusion to deliver a functional F9 gene.
2. Ciltacabtagene autoleucel BCMA CAR‑T for multiple myeloma. It expands access to a best‑in‑class myeloma CAR‑T in the world’s second‑largest market
3. Equecabtagene autoleucel Fully human BCMA CAR‑T. The First fully human BCMA CAR‑T approved in China; high ORR in RRMM (FUMANBA‑1).
4. Ivonescimab Bispecific anti‑PD‑1/anti‑VEGF‑A antibody. First approved PD‑1×VEGF‑A bispecific anywhere; combines immune checkpoint blockade with anti‑angiogenesis in one IgG. Very important for cancer.
5. Sunvozertinib Oral EGFR ex20ins TKI. Potent, selective inhibitor for EGFR exon‑20 insertion NSCLC—a notoriously hard‑to‑treat mutation.
6. Zorifertinib EGFR TKI for EGFR‑mutant NSCLC with CNS mets. First‑line indication specifically addressing CNS metastases in common EGFR mutations (del19/L858R).
7. Disitamab vedotin (RemeGen, HER2‑ADC) China’s first homegrown ADC.
8. Checkpoint antibodies from China winning US/EU approvals. Pretty big as it’s the first China‑developed PD‑1 antibody approved in the US; first immunotherapy for recurrent NPC in the US.
9. Tislelizumab (BeiGene, TEVIMBRA) also approved in the US now.
10. First‑in‑world dual GLP‑1R/GlucagonR agonist for weight management.
11. Efsubaglutide alfa (Innogen/Yinnuo). Long‑acting GLP‑1RA for type 2 diabetes.
12. A ‘PCSK9 wave’ of domestic LDL‑lowering antibodies. It’s a multiple fully human PCSK9 mAbs approved in rapid succession.
13. First mRNA COVID‑19 vaccine approved in China. This helped establish an mRNA platform in China.
14. Pradefovir mesylate Liver‑targeted prodrug for chronic hepatitis B
Introducing Qwen3!
We release and open-weight Qwen3, our latest large language models, including 2 MoE models and 6 dense models, ranging from 0.6B to 235B. Our flagship model, Qwen3-235B-A22B, achieves competitive results in benchmark evaluations of coding, math, general capabilities, etc., when compared to other top-tier models such as DeepSeek-R1, o1, o3-mini, Grok-3, and Gemini-2.5-Pro. Additionally, the small MoE model, Qwen3-30B-A3B, outcompetes QwQ-32B with 10 times of activated parameters, and even a tiny model like Qwen3-4B can rival the performance of Qwen2.5-72B-Instruct.
For more information, feel free to try them out in Qwen Chat Web (https://t.co/bg4tAU1p74) and APP and visit our GitHub, HF, ModelScope, etc.
Blog: https://t.co/Z8YgHerTXz
GitHub: https://t.co/Ij0Vne5b5K
Hugging Face: https://t.co/V1WxhQ0fad
ModelScope: https://t.co/Z9Z37FODVN
The post-trained models, such as Qwen3-30B-A3B, along with their pre-trained counterparts (e.g., Qwen3-30B-A3B-Base), are now available on platforms like Hugging Face, ModelScope, and Kaggle. For deployment, we recommend using frameworks like SGLang and vLLM. For local usage, tools such as Ollama, LMStudio, MLX, llama.cpp, and KTransformers are highly recommended. These options ensure that users can easily integrate Qwen3 into their workflows, whether in research, development, or production environments.
Hope you enjoy our new models!
非常有意思的一張圖表:
- A行表示會發生恐慌(Panic)的年份;
- B行表示好年景(Years of good times),價格高漲,適合賣出股票和有價值的東西;
- C行表示艱難時期(Years of hard times),價格走低,適合買股票和有價值的東西,持有到好年景再賣出。
這張表格由Samuel Benner在1875年繪製,準確地預測了很多重要事件。